IL36G and colitis: In addition, targeting IL‐36γ by maturation blockade or neutralization significantly inhibited colitis and colon cancer development, indicating IL‐36γ as a potential intervention target for the treatment of IBD and CRC (Figure S8E, Supporting Information).